The effect of subsequent immunosuppressant use in organ-transplanted patients on prostate cancer incidence: a retrospective analysis using the Korean National Health Insurance Database

Table 4 Subgroup analysis adjusted by the risk factors of prostate cancer prevalence

Characteristics	N	Event	Duration	IR (per 1000)	Model 1		Model 2		Model 3
Characteristics	N	Event	Duration	IR (per 1000)	HR	p value	HR	p value	HR	p value
Transplantation
No transplantation	38,910	111	190,764.2	0.58187	1 (Ref.)	< .001	1 (Ref.)	< 0.001	1 (Ref.)	0.1948
Transplantation	12,970	77	61,331.36	1.25548	2.178 (1.628,2.912)	1.965 (1.392,2.772)	0.539 (0.212,1.372)
Transplanted organ
Control	38,910	111	190,764.2	0.58187	1 (Ref.)	< .001	1 (Ref.)	< 0.001	1 (Ref.)	0.0229
1. Kidney	7026	21	33,615.34	0.62471	1.08 (0.677,1.722)	1.066 (0.629,1.806)	0.28 (0.102,0.767)
2. Liver	5445	54	25,616.58	2.10801	3.661 (2.645,5.068)	2.716 (1.876,3.931)	0.729 (0.29,1.832)
3. Pancreas	28	0	105.38	0	N.A		N.A		N.A
4. Heart	398	2	1760.07	1.13632	2.013 (0.497,8.151)	1.241 (0.297,5.179)	0.327 (0.062,1.73)
5. Lung	73	0	233.99	0	N.A		N.A		N.A

Model 1 Rude
Model 2 Adjusted by the “Age, Aspirin, Statin, Hypertension, Diabetes, Dyslipidemia”
Model 3 Adjusted by the “Age, Aspirin, Statin, Hypertension, Diabetes, Dyslipidemia, Immunosuppressant”

ISSN: 1471-2490